On April 18, 2025, at the China Valve (Hangzhou) 2025 conference, Prof. Yan Yunfeng from Prof. Song Guangyuan’s team at Beijing Anzhen Hospital presented oneyear follow-up results from the Multi-center Registration Clinical Trial of TaurusTrio™.
This prospective, multi-center, single-arm study enrolled 116 AR patients across 19 centers to evaluate the safety and efficacy of TaurusTrio™ in treating symptomatic, severe (≥3+) AR patients unsuitable for conventional surgery. All patients completed one-year follow-up by early 2024.
Baseline data: average patient age 72.5 years, mean annulus diameter 81.8 ±5.4 mm. At 30 days post-procedure, all-cause mortality was 0%, device-related reoperation 0%, and coronary obstruction 0%. At one year, all-cause mortality was 2.6%, stroke rate 0.9%, major bleeding 0.9%. Echocardiography showed 0% moderate or higher paravalvular leakage, significant left ventricular reverse remodeling, and marked improvements in cardiac function and quality of life.
At the China Valve (Hangzhou) 2025 conference, Peijia Medical showcased its transcatheter valve therapeutic products through live/recorded surgeries, topical discussions, new device symposia, JACC and case study forums, and training workshops, delivering comprehensive academic insights into the latest advancements in valve intervention.
